Health authorities in the U.S. and the U.K. have approved lenacapavir, a long-acting injectable drug designed to prevent HIV infection.
This approval provides a critical alternative for individuals who cannot adhere to daily oral pre-exposure prophylaxis (PrEP) regimens. By replacing daily pills with infrequent injections, health officials aim to reduce the number of new HIV infections worldwide.
Marketed as Yeztugo, the drug was approved in 2024 [4]. The medication is now being rolled out via the NHS in England and Wales, following approval from the U.S. Food and Drug Administration.
Reports on the administration frequency of the drug vary. Some data indicates the injection is administered two times a year [1], while other reports state the shot is given six times a year [2]. This discrepancy highlights different dosing schedules or reporting standards across regions.
The efficacy of the treatment is high. According to one report, the drug provides a 96% reduction in HIV transmission risk [3]. This level of protection is intended to bridge the gap for high-risk populations who face barriers to consistent medication use.
Unlike traditional PrEP, which requires a strict daily schedule to maintain effectiveness, lenacapavir remains in the system longer. This shift in delivery method reduces the risk of human error, and the stigma associated with daily pill consumption.
“The drug provides a 96% reduction in HIV transmission risk.”
The transition from daily oral medication to a long-acting injectable represents a shift toward 'passive' prevention. By removing the requirement for daily adherence, health authorities can better reach marginalized populations and those with unstable living conditions, potentially lowering the global baseline of new infections.
